CA3198255A1 - Ctla-4 variant immunomodulatory proteins and uses thereof - Google Patents
Ctla-4 variant immunomodulatory proteins and uses thereofInfo
- Publication number
- CA3198255A1 CA3198255A1 CA3198255A CA3198255A CA3198255A1 CA 3198255 A1 CA3198255 A1 CA 3198255A1 CA 3198255 A CA3198255 A CA 3198255A CA 3198255 A CA3198255 A CA 3198255A CA 3198255 A1 CA3198255 A1 CA 3198255A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- ctla
- cell
- domain
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 195
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 187
- 230000002519 immonomodulatory effect Effects 0.000 title claims abstract description 92
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims abstract description 378
- 229940045513 CTLA4 antagonist Drugs 0.000 claims abstract description 375
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 319
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 315
- 229920001184 polypeptide Polymers 0.000 claims abstract description 313
- 238000000034 method Methods 0.000 claims abstract description 51
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 46
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 39
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 34
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 379
- 230000027455 binding Effects 0.000 claims description 225
- 210000004027 cell Anatomy 0.000 claims description 145
- 150000001413 amino acids Chemical class 0.000 claims description 130
- 102100034980 ICOS ligand Human genes 0.000 claims description 108
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 107
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 88
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 85
- 230000009870 specific binding Effects 0.000 claims description 77
- 239000012634 fragment Substances 0.000 claims description 76
- 230000004048 modification Effects 0.000 claims description 72
- 238000012986 modification Methods 0.000 claims description 72
- 230000001965 increasing effect Effects 0.000 claims description 68
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 57
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 238000006467 substitution reaction Methods 0.000 claims description 38
- 230000028993 immune response Effects 0.000 claims description 34
- 239000000427 antigen Substances 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 210000004698 lymphocyte Anatomy 0.000 claims description 22
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 21
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 21
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 21
- 230000006870 function Effects 0.000 claims description 20
- 210000002865 immune cell Anatomy 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000013598 vector Substances 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 13
- 239000012636 effector Substances 0.000 claims description 12
- 230000008685 targeting Effects 0.000 claims description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims description 11
- 230000002757 inflammatory effect Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 102220155715 rs886062788 Human genes 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 7
- 239000013604 expression vector Substances 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 239000012678 infectious agent Substances 0.000 claims description 5
- 210000000822 natural killer cell Anatomy 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 239000000710 homodimer Substances 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 101710160107 Outer membrane protein A Proteins 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 15
- 230000001363 autoimmune Effects 0.000 abstract description 12
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 abstract description 4
- 230000004968 inflammatory condition Effects 0.000 abstract description 2
- 102220344288 rs1554032090 Human genes 0.000 description 439
- 102200101766 rs72554324 Human genes 0.000 description 337
- 102220119533 rs375389609 Human genes 0.000 description 221
- 102220032940 rs367543239 Human genes 0.000 description 175
- 235000018102 proteins Nutrition 0.000 description 162
- 102220350613 c.214A>G Human genes 0.000 description 150
- 235000001014 amino acid Nutrition 0.000 description 145
- 229940024606 amino acid Drugs 0.000 description 124
- 102200118258 rs35094013 Human genes 0.000 description 93
- 102220005270 rs33932981 Human genes 0.000 description 92
- 102220195869 rs751437780 Human genes 0.000 description 91
- 102220286033 rs1553301271 Human genes 0.000 description 85
- 102220133301 rs757905542 Human genes 0.000 description 67
- 102220218217 rs1060502513 Human genes 0.000 description 42
- 230000003247 decreasing effect Effects 0.000 description 40
- 102220251295 rs1555027633 Human genes 0.000 description 36
- 238000003556 assay Methods 0.000 description 35
- 102200025123 rs145047094 Human genes 0.000 description 34
- 241000894007 species Species 0.000 description 32
- 102200101764 rs72554320 Human genes 0.000 description 30
- 230000001086 cytosolic effect Effects 0.000 description 29
- 102200113220 rs35220041 Human genes 0.000 description 29
- 239000003446 ligand Substances 0.000 description 28
- 108091008874 T cell receptors Proteins 0.000 description 25
- 230000003993 interaction Effects 0.000 description 25
- 108060003951 Immunoglobulin Proteins 0.000 description 24
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 24
- 230000007423 decrease Effects 0.000 description 24
- 102000018358 immunoglobulin Human genes 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 23
- 230000001900 immune effect Effects 0.000 description 22
- 210000004962 mammalian cell Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 102200121805 rs1085307185 Human genes 0.000 description 21
- 102220024983 rs199473649 Human genes 0.000 description 21
- 108010052285 Membrane Proteins Proteins 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 20
- 230000011664 signaling Effects 0.000 description 20
- 102000008070 Interferon-gamma Human genes 0.000 description 19
- 108010074328 Interferon-gamma Proteins 0.000 description 19
- 102220227032 rs1064793026 Human genes 0.000 description 19
- 102220473080 HLA class II histocompatibility antigen, DP alpha 1 chain_A42V_mutation Human genes 0.000 description 18
- 102000018697 Membrane Proteins Human genes 0.000 description 18
- 229960003130 interferon gamma Drugs 0.000 description 18
- 102200135024 rs35877720 Human genes 0.000 description 18
- 102220022283 rs397509331 Human genes 0.000 description 18
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 102220005154 rs33988732 Human genes 0.000 description 16
- 239000000232 Lipid Bilayer Substances 0.000 description 15
- 102220011021 rs397507516 Human genes 0.000 description 15
- 102220098555 rs878853237 Human genes 0.000 description 14
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 13
- 230000000139 costimulatory effect Effects 0.000 description 13
- 210000000428 immunological synapse Anatomy 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 102220316328 rs1315405264 Human genes 0.000 description 13
- 102220278973 rs1554708772 Human genes 0.000 description 13
- 102220005411 rs35873730 Human genes 0.000 description 13
- 102000035160 transmembrane proteins Human genes 0.000 description 13
- 108091005703 transmembrane proteins Proteins 0.000 description 13
- 230000006044 T cell activation Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 102220340761 rs1052030 Human genes 0.000 description 12
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 11
- 102200096038 rs386834125 Human genes 0.000 description 11
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 102100021317 Inducible T-cell costimulator Human genes 0.000 description 10
- 101710205775 Inducible T-cell costimulator Proteins 0.000 description 10
- 230000004075 alteration Effects 0.000 description 10
- 230000004068 intracellular signaling Effects 0.000 description 10
- 102220344286 rs1554032090 Human genes 0.000 description 10
- 230000003213 activating effect Effects 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 210000004986 primary T-cell Anatomy 0.000 description 9
- 102200088402 rs121908653 Human genes 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- -1 CD86 Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 102200115907 rs121918081 Human genes 0.000 description 8
- 102200163544 rs63750792 Human genes 0.000 description 8
- 102220222503 rs751802145 Human genes 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
- 102220607933 C-reactive protein_E59K_mutation Human genes 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 7
- 108020004511 Recombinant DNA Proteins 0.000 description 7
- 102220579491 Transthyretin_T69I_mutation Human genes 0.000 description 7
- 102220345529 c.192C>G Human genes 0.000 description 7
- 108091008034 costimulatory receptors Proteins 0.000 description 7
- 230000016396 cytokine production Effects 0.000 description 7
- 102000043321 human CTLA4 Human genes 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102220040807 rs111826855 Human genes 0.000 description 7
- 102220561101 5'-AMP-activated protein kinase subunit gamma-1_T89S_mutation Human genes 0.000 description 6
- 102220557008 F-box/LRR-repeat protein 12_L63H_mutation Human genes 0.000 description 6
- 102220473085 HLA class II histocompatibility antigen, DP alpha 1 chain_A42T_mutation Human genes 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 6
- 238000001994 activation Methods 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 102220415904 c.104G>A Human genes 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 230000036963 noncompetitive effect Effects 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 102200017779 rs10132601 Human genes 0.000 description 6
- 102220036548 rs140382474 Human genes 0.000 description 6
- 102200003634 rs199696526 Human genes 0.000 description 6
- 102220044832 rs587781608 Human genes 0.000 description 6
- 102200046979 rs62645879 Human genes 0.000 description 6
- 102220149729 rs763469367 Human genes 0.000 description 6
- 102220073946 rs778958318 Human genes 0.000 description 6
- 102220143226 rs886058292 Human genes 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 description 5
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 5
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 description 5
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 5
- 102220578417 Transthyretin_I93V_mutation Human genes 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 108091005706 peripheral membrane proteins Proteins 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102100038077 CD226 antigen Human genes 0.000 description 4
- 102000000844 Cell Surface Receptors Human genes 0.000 description 4
- 108010001857 Cell Surface Receptors Proteins 0.000 description 4
- 102220627364 Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase_A42S_mutation Human genes 0.000 description 4
- 102220519818 Glutathione synthetase_A26D_mutation Human genes 0.000 description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 4
- 101710093458 ICOS ligand Proteins 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 4
- 102100029740 Poliovirus receptor Human genes 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 238000006640 acetylation reaction Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 229940050526 hydroxyethylstarch Drugs 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000029226 lipidation Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 102220173399 rs146534475 Human genes 0.000 description 4
- 102200155004 rs62619924 Human genes 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 102220472254 Eukaryotic translation initiation factor 4E transporter_Y54F_mutation Human genes 0.000 description 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 3
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 3
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 description 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 229960003697 abatacept Drugs 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 102220408680 c.200T>C Human genes 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 102000054189 human CD80 Human genes 0.000 description 3
- 102000049849 human CD86 Human genes 0.000 description 3
- 102000046492 human ICOSLG Human genes 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 210000000581 natural killer T-cell Anatomy 0.000 description 3
- 230000009635 nitrosylation Effects 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 102200156918 rs387906512 Human genes 0.000 description 3
- 102200159386 rs60798368 Human genes 0.000 description 3
- 102220077594 rs761906487 Human genes 0.000 description 3
- 102200031581 rs864309650 Human genes 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000010798 ubiquitination Methods 0.000 description 3
- 230000034512 ubiquitination Effects 0.000 description 3
- 102220508069 5'-3' exoribonuclease 1_G4S_mutation Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 102100024263 CD160 antigen Human genes 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- 102220622722 G protein-coupled receptor kinase 5_Q41L_mutation Human genes 0.000 description 2
- 102220596745 Gap junction alpha-1 protein_S27P_mutation Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 101000589307 Homo sapiens Natural cytotoxicity triggering receptor 3 Proteins 0.000 description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 2
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 102000017578 LAG3 Human genes 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 102220573173 Magnesium transporter NIPA4_S73R_mutation Human genes 0.000 description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 101150065403 NECTIN2 gene Proteins 0.000 description 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 2
- 108010009910 Natural Cytotoxicity Triggering Receptors Proteins 0.000 description 2
- 102000009838 Natural Cytotoxicity Triggering Receptors Human genes 0.000 description 2
- 102100035488 Nectin-2 Human genes 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 description 2
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 2
- 102220587467 Protein FAM102A_M87A_mutation Human genes 0.000 description 2
- 230000010799 Receptor Interactions Effects 0.000 description 2
- 102220616555 S-phase kinase-associated protein 2_E48R_mutation Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 description 2
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 description 2
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 2
- 101710163413 Signaling lymphocytic activation molecule Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
- 102220483110 TLC domain-containing protein 4_N75D_mutation Human genes 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 description 2
- 102220475444 Vacuolar protein sorting-associated protein 33A_V22A_mutation Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 229960005347 belatacept Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000006237 glutamylation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004964 innate lymphoid cell Anatomy 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 102220006123 rs1042713 Human genes 0.000 description 2
- 102200071072 rs104893972 Human genes 0.000 description 2
- 102220214161 rs1060501307 Human genes 0.000 description 2
- 102220068644 rs150880478 Human genes 0.000 description 2
- 102220318854 rs1554258810 Human genes 0.000 description 2
- 102220265087 rs1554817350 Human genes 0.000 description 2
- 102220011706 rs201343342 Human genes 0.000 description 2
- 102220005450 rs33939620 Human genes 0.000 description 2
- 102200082931 rs33945546 Human genes 0.000 description 2
- 102220217675 rs370859268 Human genes 0.000 description 2
- 102200029469 rs63750123 Human genes 0.000 description 2
- 102200008483 rs74315401 Human genes 0.000 description 2
- 102220094031 rs777491507 Human genes 0.000 description 2
- 102220250575 rs900324585 Human genes 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- 102220646192 Actin-like protein 7A_A31Y_mutation Human genes 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000004555 Butyrophilins Human genes 0.000 description 1
- 108010017533 Butyrophilins Proteins 0.000 description 1
- 108010062802 CD66 antigens Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102100029382 CMRF35-like molecule 6 Human genes 0.000 description 1
- 102220596352 CUGBP Elav-like family member 1_L12I_mutation Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 102220610050 Chromogranin-A_M56L_mutation Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100031351 Galectin-9 Human genes 0.000 description 1
- 101710121810 Galectin-9 Proteins 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 108700010013 HMGB1 Proteins 0.000 description 1
- 101150021904 HMGB1 gene Proteins 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101000743493 Homo sapiens V-set and immunoglobulin domain-containing protein 8 Proteins 0.000 description 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 101100468545 Mus musculus Rgmb gene Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- 102000002356 Nectin Human genes 0.000 description 1
- 108060005251 Nectin Proteins 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102220624790 Non-structural maintenance of chromosomes element 4 homolog A_S72T_mutation Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 101000831623 Rattus norvegicus Protein timeless homolog Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010043784 Thyroiditis subacute Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 102100038355 V-set and immunoglobulin domain-containing protein 8 Human genes 0.000 description 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001977 ataxic effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000037896 autoimmune cutaneous disease Diseases 0.000 description 1
- 208000001974 autoimmune enteropathy Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 108010048507 poliovirus receptor Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102220323601 rs1555225091 Human genes 0.000 description 1
- 102220328919 rs1555631387 Human genes 0.000 description 1
- 102220041129 rs529720410 Human genes 0.000 description 1
- 102220101582 rs74555599 Human genes 0.000 description 1
- 102200134465 rs80338876 Human genes 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000002446 thrombocytic effect Effects 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000003142 viral transduction method Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570619P | 2017-10-10 | 2017-10-10 | |
| US62/570,619 | 2017-10-10 | ||
| US201862613379P | 2018-01-03 | 2018-01-03 | |
| US62/613,379 | 2018-01-03 | ||
| US201862733615P | 2018-09-19 | 2018-09-19 | |
| US62/733,615 | 2018-09-19 | ||
| CA3077509A CA3077509A1 (en) | 2017-10-10 | 2018-10-09 | Ctla-4 variant immunomodulatory proteins and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3077509A Division CA3077509A1 (en) | 2017-10-10 | 2018-10-09 | Ctla-4 variant immunomodulatory proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3198255A1 true CA3198255A1 (en) | 2019-04-18 |
Family
ID=63966157
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3198255A Pending CA3198255A1 (en) | 2017-10-10 | 2018-10-09 | Ctla-4 variant immunomodulatory proteins and uses thereof |
| CA3077509A Pending CA3077509A1 (en) | 2017-10-10 | 2018-10-09 | Ctla-4 variant immunomodulatory proteins and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3077509A Pending CA3077509A1 (en) | 2017-10-10 | 2018-10-09 | Ctla-4 variant immunomodulatory proteins and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11753458B2 (enExample) |
| EP (3) | EP3694870A1 (enExample) |
| JP (3) | JP7749319B2 (enExample) |
| KR (3) | KR102813968B1 (enExample) |
| CN (2) | CN111801347A (enExample) |
| CA (2) | CA3198255A1 (enExample) |
| MA (1) | MA50360A (enExample) |
| WO (1) | WO2019074983A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3875477A1 (en) | 2015-04-17 | 2021-09-08 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| US12297253B2 (en) * | 2018-01-03 | 2025-05-13 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| KR20210124179A (ko) * | 2018-11-02 | 2021-10-14 | 베이징 브이디제이바이오 컴퍼니 리미티드 | 변형된 ctla4 및 이의 사용 방법 |
| JP7650047B2 (ja) * | 2019-11-27 | 2025-03-24 | 株式会社 MiyaCare Therapeutics | 変異型結合性タンパク質の製造方法及び変異型ｐｄ－１ |
| IL297981A (en) | 2020-05-08 | 2023-01-01 | Alpine Immune Sciences Inc | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| CN111592580A (zh) * | 2020-05-08 | 2020-08-28 | 中国药科大学 | 一种具有免疫检查点ctla-4抑制活性的多肽及其应用 |
| WO2023205796A2 (en) * | 2022-04-21 | 2023-10-26 | Ohio State Innovation Foundation | Human ctla-4 peptide vaccines and uses thereof |
| CN119679395B (zh) * | 2024-12-04 | 2025-09-23 | 山东大学 | 一种基于动力学图融合的腺样体肥大辅助检测系统及方法 |
Family Cites Families (175)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| US6218525B1 (en) | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
| US6685941B1 (en) | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| CA2102623C (en) | 1991-05-06 | 2003-04-22 | Jeffrey Schlom | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| DE69226871T3 (de) | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| EP1005870B1 (en) | 1992-11-13 | 2009-01-21 | Biogen Idec Inc. | Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| US6482919B2 (en) | 1993-02-01 | 2002-11-19 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| JP4418965B2 (ja) | 1994-09-23 | 2010-02-24 | タップイミューン・インコーポレイテッド | 内在性ペプチドを有するｍｈｃクラスｉ分子の発現を増強する方法 |
| DK0784483T3 (da) | 1994-10-03 | 2001-03-26 | Us Gov Health & Human Serv | Præparat indeholdende et rekombinant virus, der udtrykker et antigen, og et rekombinant virus, der udtrykker et immunstimul |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
| US5767071A (en) | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US20040063094A1 (en) | 1998-05-20 | 2004-04-01 | Biovex Limited | Mutant herpes simplex viruses and uses thereof |
| GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| CN1348463A (zh) | 1998-08-07 | 2002-05-08 | 华盛顿大学 | 免疫学单纯疱疹病毒抗原及其使用方法 |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
| US6365619B1 (en) | 1999-07-22 | 2002-04-02 | Novartis Ag | Treatment of arteriosclerosis |
| WO2001011034A2 (en) | 1999-08-09 | 2001-02-15 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
| PT1218504E (pt) | 1999-09-21 | 2007-10-22 | Genetics Inst Llc | Novas moléculas gl50 e suas utilizações |
| US7329728B1 (en) | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
| AU2926401A (en) | 2000-01-03 | 2001-07-16 | Tr Associates, L.L.C. | Novel chimeric proteins and methods for using the same |
| US7223593B2 (en) | 2000-01-21 | 2007-05-29 | Biovex Limited | Herpes virus strains for gene therapy |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| EG24459A (en) * | 2000-05-26 | 2009-07-16 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof |
| EP1360290A2 (en) | 2000-06-23 | 2003-11-12 | Maxygen, Inc. | Co-stimulatory molecules |
| US7183376B2 (en) | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
| RU2287340C2 (ru) | 2000-07-03 | 2006-11-20 | Бристол-Маерс Сквибб Компани | Способы лечения ревматических заболеваний с применением растворимого ctla4 |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| US7011972B2 (en) | 2000-07-18 | 2006-03-14 | The Scripps Research Institute | Fusion polypeptide comprising two ligand binding domains |
| HU229680B1 (hu) | 2001-05-23 | 2014-04-28 | Bristol Myers Squibb Co | Eljárások allogén sziget átültetés védelmére oldható CTLA4 mutáns molekulák alkalmazásával |
| KR100453877B1 (ko) | 2001-07-26 | 2004-10-20 | 메덱스젠 주식회사 | 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체 |
| US6871421B2 (en) | 2001-09-21 | 2005-03-29 | Daniel R. Potter | Footwear with bladder type stabilizer |
| CN1304559C (zh) | 2001-10-09 | 2007-03-14 | 杭州康科生物技术有限公司 | 表达热休克蛋白的溶瘤微生物及其应用 |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| DK1461073T3 (da) | 2001-11-30 | 2010-03-29 | Us Gov Health & Human Serv | Peptidagonister til prostataspecifikt antigen og anvendelser heraf |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
| TWI328614B (en) | 2002-12-23 | 2010-08-11 | Bristol Myers Squibb Co | Product quality enhancement in mammalian cell culture processes for protein production |
| EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
| BRPI0411526A (pt) | 2003-06-18 | 2006-08-01 | Genelux Corp | vìrus de vaccinia e outros microrganismos recombinates modificados e usos dos mesmos |
| WO2005016266A2 (en) | 2003-08-04 | 2005-02-24 | Bristol-Myers Squibb Company | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
| ATE554107T1 (de) | 2003-12-19 | 2012-05-15 | Genentech Inc | Als therapeutika geeignete monovalente antikörperfragmente |
| PL1737891T3 (pl) | 2004-04-13 | 2013-08-30 | Hoffmann La Roche | Przeciwciała przeciw selektynie p |
| EP2940043A1 (en) | 2004-07-15 | 2015-11-04 | Xencor, Inc. | Optimized fc variants |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| JP4958555B2 (ja) | 2004-09-22 | 2012-06-20 | 協和発酵キリン株式会社 | 安定化されたヒトＩｇＧ４抗体 |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| MX2007008017A (es) | 2004-12-31 | 2007-09-12 | Genentech Inc | Polipeptidos que se ligan a br3 y usos de los mismos. |
| DK3050963T3 (da) | 2005-03-31 | 2019-12-09 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement |
| PT1868635T (pt) * | 2005-04-06 | 2017-07-27 | Bristol Myers Squibb Co | Métodos para tratar distúrbios imunes associados a transplantação de enxerto com moléculas mutantes solúveis de ctla4 |
| JP2007103345A (ja) | 2005-09-07 | 2007-04-19 | Toyota Motor Corp | チューブ状固体高分子型燃料電池、及びチューブ状固体高分子型燃料電池の製造方法 |
| WO2007030803A2 (en) | 2005-09-09 | 2007-03-15 | Zymogenetics, Inc. | Method for preparing trimeric proteins |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| ES2439641T3 (es) | 2005-12-20 | 2014-01-24 | Bristol-Myers Squibb Company | Composiciones y procedimientos de producción de una composición |
| US8052968B2 (en) | 2006-10-16 | 2011-11-08 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
| GB0620934D0 (en) | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| JP5840837B2 (ja) | 2007-03-30 | 2016-01-06 | メモリアル スローン−ケタリング キャンサー センター | 養子移入ｔリンパ球における副刺激リガンドの構成性発現 |
| WO2008156655A2 (en) | 2007-06-15 | 2008-12-24 | Genelux Corporation | Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors |
| CA2693707A1 (en) | 2007-07-13 | 2009-03-05 | The Johns Hopkins University | B7-dc variants |
| CA2693623A1 (en) | 2007-07-18 | 2009-01-22 | Genelux Corporation | Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |
| EP2212696B1 (en) | 2007-10-25 | 2013-12-04 | Genelux Corporation | Systems and methods for viral therapy |
| AU2008319053B2 (en) | 2007-11-01 | 2012-04-26 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
| CA2706633A1 (en) | 2007-11-27 | 2009-06-04 | Viventia Biotech Inc. | Novel cancer-associated antibody and antigen |
| DK2222861T3 (en) | 2007-12-11 | 2018-02-05 | Univ North Carolina Chapel Hill | POLYPURIN-TRACT MODIFIED RETROVIRAL VECTORS |
| CN102057272B (zh) | 2008-04-09 | 2015-02-18 | 健泰科生物技术公司 | 用于免疫相关疾病的治疗的新组合物和方法 |
| US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
| EP2300023A2 (en) | 2008-05-16 | 2011-03-30 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| EP2398466B1 (en) | 2008-11-24 | 2021-02-17 | Massachusetts Institute of Technology | Methods and compositions for localized nanoparticle delivery to a tumor |
| JP5943608B2 (ja) | 2009-02-04 | 2016-07-05 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 心臓障害の治療におけるｍｉｒ−２０８およびｍｉｒ−４９９の二重ターゲティング |
| US20150359909A1 (en) | 2009-07-16 | 2015-12-17 | University College Cork-National University Of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
| EP2283810A1 (en) | 2009-07-16 | 2011-02-16 | University College Cork-National University of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
| US8840889B2 (en) | 2009-08-13 | 2014-09-23 | The Johns Hopkins University | Methods of modulating immune function |
| PL2482849T3 (pl) | 2009-09-30 | 2018-11-30 | Memorial Sloan-Kettering Cancer Center | Skojarzona immunoterapia w leczeniu nowotworu |
| US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| EP2531216B1 (en) | 2010-02-04 | 2019-03-27 | The Trustees Of The University Of Pennsylvania | Icos critically regulates the expansion and function of inflammatory human th17 cells |
| LT2536745T (lt) | 2010-02-19 | 2016-09-26 | Xencor, Inc. | Nauji ctla4-ig imunoadhezinai |
| IL323000A (en) * | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| EP2545073B1 (en) * | 2010-03-12 | 2015-09-30 | AbbVie Biotherapeutics Inc. | Ctla4 proteins and their uses |
| KR101860963B1 (ko) | 2010-04-23 | 2018-05-24 | 제넨테크, 인크. | 이종다량체 단백질의 생산 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| AU2012207356A1 (en) | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| AU2012229048B2 (en) | 2011-03-16 | 2016-01-21 | Amgen Inc | Fc variants |
| AU2012243039B2 (en) | 2011-04-08 | 2017-07-13 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| WO2012149364A1 (en) | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
| CN102836441B (zh) | 2011-06-24 | 2019-06-11 | 台北荣民总医院 | 于感染性与恶性疾病的治疗中提升免疫反应的方法 |
| PT2726101T (pt) | 2011-06-30 | 2018-11-21 | Genzyme Corp | Inibidores da ativação de células t |
| WO2013040557A2 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
| WO2013041029A1 (en) | 2011-09-23 | 2013-03-28 | Igenimed Pharmaceuticals Inc. | Novel soluble ctla4 variants |
| US8956619B2 (en) | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| KR102057356B1 (ko) | 2012-02-27 | 2019-12-18 | 아뮤닉스 파마슈티컬스, 인크. | Ｘｔｅｎ 콘주게이트 조성물 및 그의 제조 방법 |
| WO2013148049A1 (en) | 2012-03-29 | 2013-10-03 | The General Hospital Corporation | Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4) |
| DK3207938T3 (da) * | 2012-05-11 | 2020-03-16 | Medimmune Ltd | Ctla-4-varianter |
| US20130319861A1 (en) | 2012-05-30 | 2013-12-05 | Berkeley Lights, Inc. | Outputting A Droplet Of Liquid Medium From A Device For Processing Micro-Objects In The Medium |
| HK1204950A1 (en) | 2012-06-06 | 2015-12-11 | 昂考梅德药品有限公司 | Binding agents that modulate the hippo pathway and uses thereof |
| CN113138279A (zh) | 2012-06-27 | 2021-07-20 | 法姆制药有限责任公司 | 融合蛋白组合物的应用 |
| JP5857896B2 (ja) | 2012-07-06 | 2016-02-10 | 東京エレクトロン株式会社 | 成膜装置の運転方法及び成膜装置 |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013355379B2 (en) | 2012-12-04 | 2018-08-09 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| US9944689B2 (en) | 2013-03-07 | 2018-04-17 | The General Hospital Corporation | Human CTLA4 mutants and use thereof |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| AU2014236986A1 (en) | 2013-03-15 | 2015-09-03 | Biogen Ma Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
| WO2014198002A1 (en) | 2013-06-14 | 2014-12-18 | Ottawa Hospital Research Institute | A bacterium producing an interferon binding protein and uses thereof |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| US20160271218A1 (en) | 2013-06-27 | 2016-09-22 | Mor Research Applications Ltd. | Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease |
| MX384142B (es) | 2013-07-16 | 2025-03-14 | Genentech Inc | Antagonista de unión al eje pd-1 e inhibidores de tigit para usarse en el tratamiento de cáncer. |
| CN105899534B (zh) | 2014-01-15 | 2020-01-07 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体 |
| CN105916883B (zh) | 2014-01-28 | 2019-12-03 | 北京韩美药品有限公司 | 双功能融合蛋白及其制备方法和用途 |
| ES2792849T3 (es) | 2014-02-10 | 2020-11-12 | Univ Emory | Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer |
| KR20160145789A (ko) | 2014-04-25 | 2016-12-20 | 브리스톨-마이어스 스큅 컴퍼니 | 초기 ra를 갖는 대상체에서의 무약물 완화를 달성하기 위한 ctla4 화합물의 용도 |
| WO2015172305A1 (zh) | 2014-05-12 | 2015-11-19 | 上海康岱生物医药技术股份有限公司 | 抑制taci-baff复合物形成的融合蛋白及其制法和用途 |
| KR20150135148A (ko) | 2014-05-23 | 2015-12-02 | 주식회사 제넥신 | Pd-l1 융합 단백질 및 이의 용도 |
| CA2955015A1 (en) | 2014-07-15 | 2016-01-21 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
| CN120555373A (zh) | 2014-07-16 | 2025-08-29 | 特兰斯吉恩股份有限公司 | 用于表达免疫检查点调节因子的溶瘤病毒 |
| AU2015289621A1 (en) | 2014-07-16 | 2017-01-12 | Genentech, Inc. | Methods of treating cancer using TIGIT inhibitors and anti-cancer agents |
| ES2819451T3 (es) | 2014-08-08 | 2021-04-16 | Univ Leland Stanford Junior | Agentes PD-1 de alta afinidad y procedimientos de uso |
| WO2016034678A2 (en) | 2014-09-03 | 2016-03-10 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
| US20160145344A1 (en) | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
| CA2966988A1 (en) | 2014-11-06 | 2016-05-12 | Children's Research Institute, Children's National Medical Center | Immunotherapeutics for cancer and autoimmune diseases |
| EP3020816A1 (en) | 2014-11-11 | 2016-05-18 | University College Cork | Bacterial mediated gene therapy |
| WO2016118577A1 (en) | 2015-01-22 | 2016-07-28 | Medimmune, Llc | Thymosin-beta-four fusion proteins |
| EP3277313B1 (en) | 2015-04-02 | 2021-06-23 | Cancure Limited | Agents and compositions for eliciting an immune response |
| EP3875477A1 (en) | 2015-04-17 | 2021-09-08 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| SMT202100527T1 (it) | 2015-07-30 | 2021-11-12 | Macrogenics Inc | Molecole di legame a pd-1 e lag-3 e loro metodi d'uso |
| WO2017023749A1 (en) | 2015-07-31 | 2017-02-09 | Tarveda Therapeutics, Inc. | Compositions and methods for immunomodulation |
| BR112018004965A2 (pt) | 2015-09-14 | 2018-10-09 | Alpine Immune Sciences Inc | domínios de superfamìlia de imunoglobulina variante ajustàvel |
| JP7148399B2 (ja) * | 2015-11-04 | 2022-10-05 | タイペイ・ベテランズ・ジェネラル・ホスピタル | 悪性疾患に対する併用療法 |
| SG11201804839WA (en) | 2015-12-14 | 2018-07-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
| CA3019199A1 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Icos ligand variant immunomodulatory proteins and uses thereof |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| CA3022331A1 (en) | 2016-05-18 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| SG11201903302UA (en) | 2016-10-14 | 2019-05-30 | Xencor Inc | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
| AU2017345764A1 (en) | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| IL320149A (en) | 2017-03-16 | 2025-06-01 | Alpine Immune Sciences Inc | Pd-l1 variant immunomodulatory proteins and uses thereof |
| CA3053812A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l2 variant immunomodulatory proteins and uses thereof |
| IL319966A (en) | 2017-03-16 | 2025-05-01 | Alpine Immune Sciences Inc | CD80 Variant Immune Modulator Proteins and Uses Thereof |
| KR102813968B1 (ko) | 2017-10-10 | 2025-05-29 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Ctla-4 변이체 면역조절 단백질 및 이의 용도 |
| TW202500579A (zh) | 2017-10-18 | 2025-01-01 | 美商艾爾潘免疫科學有限公司 | 變異型icos 配位體免疫調節蛋白及相關組合物及方法 |
| US12297253B2 (en) | 2018-01-03 | 2025-05-13 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| WO2020047329A1 (en) | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Chimeric proteins comprising extracellular domains and uses thereof |
| WO2020113141A2 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| IL297981A (en) | 2020-05-08 | 2023-01-01 | Alpine Immune Sciences Inc | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
-
2018
- 2018-10-09 KR KR1020237003305A patent/KR102813968B1/ko active Active
- 2018-10-09 US US16/755,072 patent/US11753458B2/en active Active
- 2018-10-09 WO PCT/US2018/055095 patent/WO2019074983A1/en not_active Ceased
- 2018-10-09 CA CA3198255A patent/CA3198255A1/en active Pending
- 2018-10-09 EP EP18793148.0A patent/EP3694870A1/en active Pending
- 2018-10-09 MA MA050360A patent/MA50360A/fr unknown
- 2018-10-09 CN CN201880077176.3A patent/CN111801347A/zh active Pending
- 2018-10-09 KR KR1020207012697A patent/KR102758545B1/ko active Active
- 2018-10-09 CN CN202510950234.0A patent/CN121021670A/zh active Pending
- 2018-10-09 EP EP23153416.5A patent/EP4219540A3/en not_active Withdrawn
- 2018-10-09 EP EP24180271.9A patent/EP4442268A3/en active Pending
- 2018-10-09 CA CA3077509A patent/CA3077509A1/en active Pending
- 2018-10-09 JP JP2020520253A patent/JP7749319B2/ja active Active
- 2018-10-09 KR KR1020257001803A patent/KR20250020681A/ko active Pending
-
2023
- 2023-01-30 US US18/161,799 patent/US20230250152A1/en active Pending
- 2023-06-26 JP JP2023104092A patent/JP2023138962A/ja active Pending
- 2023-07-20 US US18/355,539 patent/US12358969B2/en active Active
-
2025
- 2025-06-26 US US19/250,472 patent/US20250320272A1/en active Pending
- 2025-07-10 JP JP2025116732A patent/JP2025148471A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3077509A1 (en) | 2019-04-18 |
| CN111801347A (zh) | 2020-10-20 |
| US20240158463A1 (en) | 2024-05-16 |
| EP3694870A1 (en) | 2020-08-19 |
| JP2025148471A (ja) | 2025-10-07 |
| US20200308249A1 (en) | 2020-10-01 |
| US20230250152A1 (en) | 2023-08-10 |
| JP2020536552A (ja) | 2020-12-17 |
| MA50360A (fr) | 2020-08-19 |
| JP7749319B2 (ja) | 2025-10-06 |
| US11753458B2 (en) | 2023-09-12 |
| WO2019074983A1 (en) | 2019-04-18 |
| EP4442268A3 (en) | 2025-04-02 |
| CN121021670A (zh) | 2025-11-28 |
| EP4219540A3 (en) | 2023-12-06 |
| KR20200074137A (ko) | 2020-06-24 |
| KR102758545B1 (ko) | 2025-01-23 |
| US20250320272A1 (en) | 2025-10-16 |
| KR20230020022A (ko) | 2023-02-09 |
| US12358969B2 (en) | 2025-07-15 |
| EP4442268A2 (en) | 2024-10-09 |
| KR102813968B1 (ko) | 2025-05-29 |
| JP2023138962A (ja) | 2023-10-03 |
| KR20250020681A (ko) | 2025-02-11 |
| EP4219540A2 (en) | 2023-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11498967B2 (en) | CD80 variant immunomodulatory proteins and uses thereof | |
| US12110339B2 (en) | ICOS ligand variant immunomodulatory proteins and uses thereof | |
| US12358969B2 (en) | CTLA-4 variant immunomodulatory proteins and uses thereof | |
| US12297253B2 (en) | Multi-domain immunomodulatory proteins and methods of use thereof | |
| US11834490B2 (en) | CD112 variant immunomodulatory proteins and uses thereof | |
| EP3697810B1 (en) | Variant icos ligand immunomodulatory proteins and related compositions and methods | |
| US11471488B2 (en) | CD155 variant immunomodulatory proteins and uses thereof | |
| JP2020536552A5 (enExample) | ||
| HK40106341A (en) | Pd-l1 variant immunomodulatory proteins and uses thereof | |
| HK40031114A (en) | Ctla-4 variant immunomodulatory proteins and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230428 |
|
| EEER | Examination request |
Effective date: 20230428 |
|
| EEER | Examination request |
Effective date: 20230428 |
|
| EEER | Examination request |
Effective date: 20230428 |
|
| EEER | Examination request |
Effective date: 20230428 |
|
| EEER | Examination request |
Effective date: 20230428 |